# US 2026/0034202 A1 · Payload delivery system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0034202 A1
- Document ID: US20260034202A1
- Status: Published application
- Kind: A1
- Application number: 18/707,877
- Filed: 2022-11-10
- Published: 2026-02-05
- Earliest claimed: 2021-11-10
- Assignees: Imperial College Innovations Limited
- Applicants: Imperial College Innovations Limited
- Inventors: Rongjun Chen; Apanpreet K. Bhamra; Robin Shattock; Anna Blakney
- Web page: https://patentgrep.com/patent/US20260034202A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 47/6915: {the form being a liposome with polymerisable or polymerized bilayer-forming substances, e.g. polymersomes}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/6093: {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- C12N 2760/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16071: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure provides a sub-micron particle comprising a first payload molecule, a lipid structure and a plurality of amphiphilic polymer chains surrounding the lipid structure. The first payload molecule is a macromolecule, optionally a nucleic acid. Additionally, the hydrophobicity of the amphiphilic polymer chains changes in response to an external stimulus.

## Claims

### Claim 1

A sub-micron particle comprising a first payload molecule, a lipid structure and a plurality of amphiphilic polymer chains surrounding the lipid structure, wherein the first payload molecule is a macromolecule, optionally a nucleic acid, and the hydrophilicity of the amphiphilic polymer chains changes in response to an external stimulus.

### Claim 2 (depends on 1)

The sub-micron particle according to claim 1, wherein the first payload molecule is encapsulated in the lipid structure, and alternatively or additionally, covalently conjugated and/or physically attached to the outer surface of the lipid structure; and/or
wherein the first payload molecule is a nucleic acid, a peptide, an affimer, a protein, an antibody or a fragment thereof, a glycoprotein, a lipopolysaccharide, a carbohydrate, a lipid or a macrocycle, and is optionally a nucleic acid, and the nucleic acid is DNA, RNA or a DNA/RNA hybrid sequence, optionally wherein the RNA is self-amplifying RNA (saRNA) or messenger RNA (mRNA);
and/or
wherein the lipid structure is a lipid nanoparticle or a liposome, and is optionally a lipid nanoparticle.

### Claim at position 3

3-6. (canceled)

### Claim 7 (depends on 1)

The sub-micron particle according to claim 1, wherein the lipid structure comprises a plurality of lipids; optionally wherein at least one of the plurality of lipids comprises a cationic or ionizable lipid; optionally wherein the cationic or ionizable lipid:
(i) is a multivalent cationic lipid, or is a pH-sensitive lipid;
(ii) comprises a positively charged or ionizable nitrogen atom; and/or
(iii) displays a positive charge in an acidic solution.

### Claim at position 5

8-9. (canceled)

### Claim 10 (depends on 7)

The sub-micron particle according to claim 7, wherein at least one of the plurality of lipids comprises a cationic or ionizable lipid and the cationic or ionizable lipid is dioleoyl-3-trimethylammonium propane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), an ethylphosphatidylcholine (ethyl PC), didodecyldimethylammonium bromide (DDAB), 3β-[N—(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-Cholesterol), N4-Cholesteryl-Spermine (GL67), 1,2-dioleyloxy-3-dimethylaminopropane (DODMA), DLin-MC3-DMA, 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), or heptadecan-9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate (SM-102); and/or
wherein the plurality of lipids comprises one or more helper lipids, optionally wherein:
(i) the helper lipids are zwitterionic, optionally a phosphatidylcholine selected from DOPC, DSPC, DPPC, DDPC, DLPC, DMPC, POPC, DEPC, and L-α-phosphatidylcholine; or a phosphatidylethanolamine selected from DOPE, DMPE, DPPE, and DSPE; or
(ii) the helper lipids are non-zwitterionic, optionally a phosphatidylglycerol selected from DOPG, DMPG, DPPG, DSPG, and POPG), a phosphatidylserine (including DOPS) or a phosphatidic acid selected from DMPA, DPPA, and DSPA.

### Claim 11

(canceled)

### Claim 12 (depends on 7)

The sub-micron particle according to claim 7, wherein the sub-micron particle does not contain or comprise zwitterionic lipids.

### Claim 13 (depends on 7)

The sub-micron particle according to claim 7, wherein at least one of the plurality of lipids comprises a zwitterionic lipid, optionally wherein the zwitterionic lipid comprises a positively charged nitrogen atom and/or a negatively charged oxygen atom.

### Claim 14

(canceled)

### Claim 15 (depends on 7)

The sub-micron particle according to claim 7, wherein at least one of the plurality of lipids comprises a cationic or ionizable lipid and one or more helper lipids and wherein the weight ratio of the cationic or ionizable lipid to the helper lipid is between 20:1 and 1:20, between 10:1 and 1:10, between 5:1 and 1:5, between 4:1 and 1:4, between 3:1 and 1:3, between 2:1 and 1:2, between 1.5:1 and 1:1.5 or between 1.8:1 and 1:1.8, optionally about 1:1; and/or
wherein the plurality of lipids comprises at least 5 wt %, at least 10 wt %, at least 20 wt %, at least 30 wt % or at least 40 wt % sterol, optionally wherein the sterol is or comprises a C1-24 alkyl phytosterol, stigmasterol or stigmastanol, and is optionally cholesterol; and/or
wherein at least one of the plurality of lipids comprise a PEGylated lipid, optionally wherein the PEGylated lipid comprises between 0.1 and 50 wt %, between 0.5 and 40 wt %, between 1 and 30 wt %, between 2 and 20 wt %, between 3 and 10 wt %, between 4 and 8 wt % or between 5 and 7 wt % of the plurality of lipids.

### Claim at position 12

16-18. (canceled)

### Claim 19 (depends on 1)

The sub-micron particle according to claim 1, wherein the sub-micron particle has an N/P ratio of between 1:100 and 100:1, between 1:50 and 80:1, between 1:10 and 60:1, between 1:5 and 50:1, between 1:3 and 40:1, between 1:2 and 30:1, between 1:1 and 25:1, between 2:1 and 20:1, between 5:1 and 15:1, or between 8:1 and 12:1; and/or
wherein the external stimulus is:
(i) a chemical stimulus, which is selected from a change in pH, a specific redox potential, a specific ion or a specific gas;
(ii) a physical stimulus, which is selected from a temperature variation, a change in light or an electromagnetic field; or
(iii) a biochemical stimulus, which is selected from a protein, a peptide, an enzyme, a glucose or a nucleic acid, such as DNA; and/or
wherein the amphiphilic polymer chains are negatively charged at a pH of at least 4 at 20° C., at least 5 at 20° C., at least 6 at 20° C., at least 6.5 at 20° C. or at least 7 at 20° C.; and/or
wherein the amphiphilic polymer chains have a number average molecular weight of at least 1 kDa, at least 2 kDa, at least 5 kDa, at least 10 kDa, at least 15 kDa, at least kDa, at least 22 kDa, at least 24 kDa, at least 24.5 kDa or at least 24.8 kDa, or less than 250 kDa, less than 100 kDa, less than 75 kDa, less than 50 kDa, less than 40 kDa, less than 30 kDa, less than 28 kDa, less than 26 kDa, less than 25.5 kDa or less than 25 kDa; and/or
wherein the sub-micron particle comprises at least one targeting ligand or moiety, is or comprises at least one of a peptide, a protein, an aptamer, a carbohydrate, an oligosaccharide, a folic acid or folate, and antibody or an antigen binding fragment thereof, a vitamin or a derivative thereof.

### Claim at position 14

20-21. (canceled)

### Claim 22 (depends on 1)

The sub-micron particle according to claim 1, wherein the amphiphilic polymer chains comprise one or more mers of formula I:
wherein L1 comprises one or more linker elements selected from the group consisting of an optionally substituted C1-30 alkylene, an optionally substituted C2-30 alkenylene, an optionally substituted C2-30 alkynylene, an optionally substituted C3-20 cycloalkylene, an optionally substituted C3-20 cycloalkenylene, an optionally substituted C3-20 cycloalkynylene, an optionally substituted C3-12 heterocyclylene, an optionally substituted C6-20 arylene, an optionally substituted C5-10 heteroarylene, CO, O, S and NR4; L2 and L3 are independently absent or comprise one or more linker elements selected from the group consisting of an optionally substituted C1-30 alkylene, an optionally substituted C2-30 alkenylene, an optionally substituted C2-30 alkynylene, an optionally substituted C3-20 cycloalkylene, an optionally substituted C3-20 cycloalkenylene, an optionally substituted C3-20 cycloalkynylene, an optionally substituted C3-12 heterocyclylene, an optionally substituted C6-20 arylene, an optionally substituted C5-10 heteroarylene, CO, O, S and NR4;
each R1 is independently NR6R7, OR10 or OH;
R4 is H, an optionally substituted C1-30 alkyl, an optionally substituted C2-30 alkenyl or an optionally substituted C2-30 alkynyl;
R6 and R7 are each independently H, an optionally substituted C1-30 alkyl, an optionally substituted C2-30 alkenyl or an optionally substituted C2-30 alkynyl; and
R10 is an optionally substituted C1-30 alkyl, an optionally substituted C2-30 alkenyl or an optionally substituted C2-30 alkynyl; optionally
wherein at least one of the mers of formula I, R1 is OH; and/or
wherein the amphiphilic polymer chains comprise one or more mers of formula II:
wherein L4 comprises one or more linker elements selected from the group consisting of an optionally substituted C1-30 alkylene, an optionally substituted C2-30 alkenylene, an optionally substituted C2-30 alkynylene, an optionally substituted C3-20 cycloalkylene, an optionally substituted C3-20 cycloalkenylene, an optionally substituted C3-20 cycloalkynylene, an optionally substituted C3-12 heterocyclylene, an optionally substituted C6-20 arylene, an optionally substituted C5-10 heteroarylene, CO, O, S and NR4.

### Claim at position 16

23-24. (canceled)

### Claim 25 (depends on 22)

The sub-micron particle according to claim 22, wherein the amphiphilic polymer chains are or comprise a plurality of polymers of formula III:
wherein
X1 is absent or is O, S or NR5;
R2 is H, an optionally substituted C1-30 alkyl, an optionally substituted C2-30 alkenyl, an optionally substituted C2-30 alkynyl, an optionally substituted C6-20 aryl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C3-20 cycloalkenyl, an optionally substituted C3-20 cycloalkynyl, an optionally substituted 5 to 20 membered heteroaryl or an optionally substituted 3 to 20 membered heterocycle;
R3 and R5 are each independently H, an optionally substituted C1-30 alkyl, an optionally substituted C2-30 alkenyl or an optionally substituted C2-30 alkynyl; and
n is an integer and is at least 1; and
m is 0 or is an integer which is at least 1; optionally
wherein:
(i) there is one or more -L4- blocks, which may be same or different from each other;
(ii) there is one or more -L1-CH(L3-COR1)-L2- blocks, which may be same or different from each other; and/or
(iii) the polymers have a random or controlled sequence; or
wherein the amphiphilic polymer chains are or comprise a plurality of polymers of formula IV:
optionally wherein the polymer of formula IV has formula IVa:

### Claim at position 18

26-28. (canceled)

### Claim 29 (depends on 22)

The sub-micron particle according to claim 22, wherein between 1 and 99%, between 5 and 85%, between 10 and 60% or between 15 and 40% of the R1 group in the polymers are OH, and between 1 and 99%, between 15 and 95% of the R1 group in the polymers are NR6R7 or OR10; optionally wherein between 1 and 99%, between 15 and 95%, between 40 and 90% or between 60 and 85% of the R1 group in the polymers are NR6R7, R6 is H and R7 is
or
between 1 and 99%, between 5 and 90%, between 10 and 80%, between 12.5 and 70% or between 15 and 65% of the R1 group in the polymers are NR6R7, R6 is H and R7 is —(CH2)6CH3,
(CH2)9CH3, —(CH2)13CH3, —(CH2)17CH3 or —(CH2)11COOH.

### Claim at position 20

30-32. (canceled)

### Claim 33 (depends on 25)

The sub-micron particle according to claim 25, wherein:
(i) n is an integer of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 or at least 8;
(ii) n is an integer of less than 50, less than 40, less than 30, less than 25, less than 20, less than 15, less than 12 or less than 10;
(iii) n is an integer between 1 and 50, between 2 and 40, between 3 and 30, between 4 and 25, between 5 and 20, between 6 and 15, between 7 and 12 or between 8 and 10;
(iv) n is an integer of at least 5, at least 10, at least 15, at least 25, at least 50, at least 75, at least 90 or at least 95. n may be an integer of less than 5,000, less than 1,000, less than 500, less than 250, less than 150, less than 125, less than 110 or less than 105. n may be an integer between 5 and 5,000, between 10 and 1,000, between 15 and 500, between 25 and 250, between 50 and 150, between 75 and 125, between 90 and 110 or between 95 and 105.
(v) n is an integer of between 10 and 1,000, between 15 and 750, between 25 and 500, between 40 and 250, between 60 and 200, between 90 and 170, between 110 and 150, or between 120 and 140;
(vi) n is an integer of at least 100, at least 250, at least 500, at least 750, at least 1,000, at least 1,250 or at least 1,500;
(vii) m is an integer of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40 or at least 45;
(viii) m is an integer of less than 1,000, less than 500, less than 250, less than 150, less than 100, less than 80, less than 70, less than 60 or less than 55; or
(ix) m is an integer between 5 and 1,000, between 10 and 500, between 15 and 250, between 20 and 150, between 25 and 100, between 30 and 80, between 35 and 70, between 40 and 60 or between 45 and 55.

### Claim 34 (depends on 1)

The sub-micron particle according to claim 1, wherein the polymer is polymer L100F50, having the structure:

### Claim 35 (depends on 1)

The sub-micron particle according to claim 1, wherein the sub-micron particle comprises a second payload molecule, optionally
wherein the second payload molecule is encapsulated in the lipid structure, and alternatively or additionally, covalently conjugated and/or physically attached to the outer surface of the lipid structure; and/or
wherein the second payload molecule is an active pharmaceutical ingredient (API), or a component thereof, or facilitator or enabler thereof, or a macromolecule or a small molecule, optionally wherein the second payload molecule has a molecular weight of less than 900 daltons, less than 800 daltons, less than 700 daltons, less than 600 daltons, less than 500 daltons or less than 400 daltons.

### Claim 36

(canceled)

### Claim 37 (depends on 1)

The sub-micron particle according to claim 1, wherein the sub-micron particle comprises at least one stabilizing molecule; optionally wherein the or each stabilizing molecules may be a carbohydrate and/or a polyol; optionally wherein
(i) the carbohydrate is a monosaccharide, which is selected from a group consisting of: glucose; galactose; fructose; mannose; and xylose or a pharmaceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer or polymorphic form thereof;
(ii) the carbohydrate may be a disaccharide, which is selected from a group consisting of: trehalose; sucrose; lactose; maltose; isomaltose; lactitol; lactulose; mannobiose; and isomalt or a pharmaceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer or polymorphic form thereof;
(iii) the carbohydrate is a trisaccharide, which is selected from a group consisting of: nigerotriose; maltotriose: melezitose; maltotriulose; raffinose; and kestose or a pharmaceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer or polymorphic form thereof; or
(iv) the carbohydrate is a polysaccharide, which is selected from the group consisting of: dextran; amylose: amylopectin; glycogen; galactogen; inulin; callose; cellulose: chitosan; and chitin or a pharmaceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer or polymorphic form thereof; or
wherein
the carbohydrate is trehalose, or a pharmaceutically acceptable complex, salt, solvate, tautomeric form, stereoisomer or polymorphic form thereof.

### Claim at position 26

38-41. (canceled)

### Claim 42

A method of producing a sub-micron particle, the method comprising combining a first payload molecule, a lipid structure and a plurality of amphiphilic polymer chains to produce the sub-micron particle, wherein the first payload molecule is a macromolecule, optionally a nucleic acid, and the hydrophilicity of the amphiphilic polymer chains changes in response to an external stimulus.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the method comprises contacting the first payload molecule and a plurality of lipids to produce a lipid structure encapsulating, or being covalently conjugated and/or physically attached onto its outer surface with, the first payload molecule, and subsequently contacting the lipid structure and the plurality of amphiphilic polymer chains to produce the sub-micron particle; and/or
wherein the method comprises contacting the first payload molecule, a second payload molecule and a plurality of lipids to produce a lipid structure encapsulating, or being covalently conjugated and/or physically attached onto its outer surface with, the first and second payload molecules; and subsequently contacting the lipid structure and the plurality of amphiphilic polymer chains to produce the sub-micron particle; and/or
wherein the method is used to modify the existing lipid structure, including lipid nanoparticle and liposome systems.

### Claim at position 29

44-46. (canceled)

### Claim 47 (depends on 1)

A composition comprising a plurality of sub-micron particles of claim 1, optionally wherein the composition is a pharmaceutical composition and comprises a pharmaceutically acceptable vehicle.

### Claim at position 31

48-49. (canceled)

### Claim 50 (depends on 1)

A vaccine composition comprising the sub-micron particle of claim 1.

### Claim 51

(canceled)

### Claim 52 (depends on 1)

A method of vaccinating a subject, the method comprising administering, or having administered, to a subject in need thereof, a therapeutic amount of the sub-micron particle of claim 1.
